Free shipping on all orders over $ 500

Dotinurad

Cat. No. M10691
Dotinurad Structure
Synonym:

FYU-981

Size Price Availability Quantity
5mg USD 355  USD355 In stock
10mg USD 630  USD630 In stock
25mg USD 1060  USD1060 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Dotinurad is a potent selective urate reabsorption inhibitor. Dotinurad inhibits Urate Transporter 1 (URAT1), IC50 value is 37.2 nM. Dotinurad is used as a uric acid-enhancing excretor.

Chemical Information
Molecular Weight 358.20
Formula C14H9Cl2NO4S
CAS Number 1285572-51-1
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Tomohiko Ishikawa, et al. Expert Opin Pharmacother. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout

[2] Koichi Omura, et al. Drug Metab Pharmacokinet. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor

[3] Tatsuo Hosoya, et al. Clin Exp Nephrol. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

[4] Yuji Kumagai, et al. Clin Exp Nephrol. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment

[5] Satoru Kuriyama. Clin Exp Nephrol. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia

Related URAT1 Products
KPH2f

KPH2f is an orally potent dual URAT1/GLUT9 inhibitor, with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively.KPH2f had little effect on OAT1 and ABCG2 (IC50s of 32.14 and 26.74 μM, respectively).

URAT1 inhibitor 8

URAT1 inhibitor 8 is a potent URAT1 inhibitor with an IC50 of 0.001 μM.URAT1 inhibitor 8 can be used in gout related studies.

URAT1 inhibitor 1

URAT1 inhibitor 1 is a uric acid transporter 1 (URAT1) inhibitor with an IC50 value of 32 nM for inhibition of uric acid transporter 1 (URAT1).It can be used in studies related to hyperuricemia and gout.

URAT1 inhibitor 3

URAT1 inhibitor 3 is an orally potent and selective URAT1 inhibitor with an IC50 value of 0.8 nM.URAT1 inhibitor 3 has a uric acid lowering effect and can be used in studies related to gout and hyperuricemia.

AR882

AR882 is a potential best-in-class (BIC), selective inhibitor of uric acid transporter protein 1 (URAT1) for studies related to hyperuricemia and gout.

  Catalog
Abmole Inhibitor Catalog




Keywords: Dotinurad, FYU-981 supplier, URAT1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.